Revolution Medicines' pancreatic cancer drug Raxonerib wins FDA approval…shares flat

1. 1Revolution Medicines (RVMD) said Raxonerib (daraxonrasib) has received FDA approval as a treatment for advanced pancreatic cancer—its first commercial drug—with shares flat on Wednesday
2. 2It is a once-daily tablet for adults with metastatic pancreatic ductal adenocarcinoma who have received at least one prior line of systemic therapy or cannot receive combination chemotherapy, with a wholesale acquisition cost of $39,800 for a 30-day supply
3. 3Investors are watching for insurance reimbursement coverage; the median overall survival in clinical trials was 13.2 months, a 60% lower risk of death compared with 6.7 months for standard chemotherapy

Source The New York Times +3 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →